Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Accumulated Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Accumulated Expenses for 12 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 192.67% to $3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, up 192.67% year-over-year, with the annual reading at $3.1 million for FY2025, 192.67% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $3.1 million at ImmunityBio, up from $2.1 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $3.1 million in Q4 2025, with the low at $556000.0 in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $1.6 million, with a median of $1.5 million recorded in 2022.
  • Peak annual rise in Other Accumulated Expenses hit 702.7% in 2021, while the deepest fall reached 70.56% in 2021.
  • Over 5 years, Other Accumulated Expenses stood at $2.6 million in 2021, then tumbled by 37.26% to $1.6 million in 2022, then plummeted by 56.02% to $716000.0 in 2023, then surged by 46.65% to $1.0 million in 2024, then surged by 192.67% to $3.1 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $3.1 million, $2.1 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.